K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
Shaul G. Massry(University of Southern California), John M. Newmann, David Churchill(The Royal Wolverhampton NHS Trust), Alan Collins(Nottingham Trent University), Mark Monteforte, Miroslaw Smogorzewski(University of Southern California), Vivian Coates, Richard H. Grimm(Cleveland Clinic), Donald J. Sherrand, Frank A. Gotch, Maureen Michael, George R. Bailie, Ronald J. Hogg, James T. McCarthy(Mayo Clinic), Glenn M. Chertow(Stanford Health Care), Peter Crooks, Jerrilynn D. Burrowes, Stephen Tregear, Joel Greer, Karyn A. Tappe, Hartmut H. Malluche(University of Kentucky), Dick de Zeeuw(University Medical Center Groningen), Craig B. Langman(Northwestern University), Charles M. Turkelson, Wendy Bruening, Kévin Martin(Bridge University), Bryan Becker, Antonio M. Gotto(Cornell University), Alan R. Hull, Francesco Locatelli(University of Modena and Reggio Emilia), Roger Greenwood, Sharon M. Moe(Indiana University School of Medicine), Fernando Carrera, Sally D. McCulloch, Janice L Kaczmarek, Keith A. Hruska(Washington University in St. Louis), Isidro B. Salusky(University of California, Los Angeles), Linda McCann, William E. Haley, Lawrence G. Hunsicker(University of Iowa), Norbert Lameire(Ghent University Hospital), Joseph V. Nally, Gavin J. Becker, Kline Bolton(University of Virginia), Saulo Klahr, Cynda Ann Johnson, Jack W. Coburn(United States Department of Veterans Affairs), James Reston(ECRI Institute), Michael J. Klag(Johns Hopkins University), Thomas A. Golper
Data Archiving and Networked Services (DANS)
October 1, 2003
Cited by 2,538
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k